President Donald Trump on Saturday signed an executive order aimed at encouraging expanded research into psychedelic drugs, part of a broader push to explore emerging mental health treatments.
“In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans,” Trump said during a signing event in the Oval Office.
The president also announced that the federal government is making a $50 million investment for further research into the psychedelic drug ibogaine.
Trump, ahead of signing the order, pointed to initial research he
Our editorial team includes several staff writers, each contributing their specialized knowledge to enhance the depth and breadth of our event and story coverage.